Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the five analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year target […]
Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is pleased to announce MarketDesign Consulting Founder + CMO Kara Rudy has ...
RICHMOND HILL, ON, Jan. 22, 2024 /PRNewswire/ -- Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is pleased to announce
/PRNewswire/ -- The "Bioinformatics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The high growth rate of...
Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca (AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.